Clarity Rapid-Response EEG by Ceribell: status and timeline

Milestones

No announced next step

First FDA clearance for adult seizure detection2023Complete.
FDA clearance for pediatric seizure detection2025Complete.
FDA clearance for neonatal seizure detectionNov 2025Complete.

Most important updates

Ceribell raises 2026 revenue guidance to $114–117M following strong Q2 with 33% YoY growthAug 2026
FDA clears Ceribell Clarity algorithm for neonatal seizure detection, expanding to all patient agesNov 2025

Current obstacles

Artifact detection in ICU settingsICUs contain many sources of electrical noise from monitors, ventilators and other equipment that can interfere with EEG signals.
Expansion beyond seizure detectionExtending AI algorithms to reliably detect other ICU conditions like delirium requires different training data and validation.

Physics limits

EEG signal attenuation through skullBrain electrical signals must pass through the skull, which dampens them significantly, so surface EEG measures weaker signals than direct recordings.
Patient-specific variabilityEEG patterns vary widely between patients, so algorithms trained on one population may not generalize perfectly to different demographics or ages.

How it works

3 parts

EEG Recording

Rapid electrode placement and signal acquisition

The Clarity system uses a portable EEG headset that can be applied quickly in the ICU, acquiring continuous brain electrical activity.

AI Analysis

Real-time pattern recognition

Machine learning algorithms analyze the EEG signal continuously, identifying patterns of electrographic seizures that may be invisible to human observers.

Clinical Alerts

Immediate notification to clinicians

When a seizure is detected, the system alerts ICU staff in real time, enabling rapid intervention before the patient shows visible symptoms.

Spec sheet

Spec	Clarity Rapid-Response EEG
Q2 2026 revenue	$28.1M^R (reported)
YoY revenue growth (Q2 2026)	33%^R (reported)
Full-year 2026 revenue guidance	$114–117M^R (reported)
Full-year 2026 growth guidance	28–31% YoY^R (reported)

^R reported by the company

Update log

2 updates

Aug 2026

Major: Ceribell raises 2026 revenue guidance to $114–117M following strong Q2 with 33% YoY growthPressCommercial

Nov 2025

Major: FDA clears Ceribell Clarity algorithm for neonatal seizure detection, expanding to all patient agesPressRegulatory

About Ceribell

The team behind Clarity Rapid-Response EEG

Ceribell

Clarity rapid-response EEG, AI seizure detection

Ceribell develops the Ceribell System, a portable EEG platform combining hardware and AI to rapidly detect seizures in ICU settings. The company trades on Nasdaq under CBLL.

The Clarity System reduces ICU stay by 4.1 days and door-to-EEG time by 19.4 hours via AI seizure detection.
Q2 2026 revenue grew 33% YoY to $28.1M; full-year guidance of $114–117M (+28–31%).
FDA cleared Clarity for neonatal seizure detection, the first AI EEG for all ages from newborns to adults.

ceribell.com (opens ceribell.com)Company profile →

Founded: 201412 yrs
Headquarters: United States
Status: Public
Listed: CBLL (opens google.com)NASDAQ
Valuation: public
Last round: IPO2024
Works in: NeurotechNon-invasive
Coverage: 1 program · 2 updateslatest 1 Aug 2026checked 11 Oct
Partners: Stanford University
People: Xingjuan (Jane) ChaoCo-Founder, President, and CEOJosef ParviziCo-Founder, Professor of Neurology at Stanford

Spec

Clarity Rapid-Response EEG

Q2 2026 revenue

$28.1M^R (reported)

YoY revenue growth (Q2 2026)

33%^R (reported)

Full-year 2026 revenue guidance

$114–117M^R (reported)

Full-year 2026 growth guidance

28–31% YoY^R (reported)